The secret ally: immunostimulation by anticancer drugs

被引：566

作者：

Galluzzi, Lorenzo ^{[1
,2
]}

Senovilla, Laura ^{[1
,2
]}

Zitvogel, Laurence ^{[1
,2
,3
]}

Kroemer, Guido ^{[1
,4
,5
,6
]}

机构：

[1] Inst Gustave Roussy, INSERM, U848, F-94805 Villejuif, France

[2] Univ Paris 11, F-94276 Le Kremlin Bicetre, France

[3] Inst Gustave Roussy, Ctr Clin Invest Biotherapies Canc CICBT 507, F-94805 Villejuif, France

[4] Ctr Rech Cordeliers, F-75006 Paris, France

[5] Hop Europeen Georges Pompidou, AP HP, F-75008 Paris, France

[6] Univ Paris 05, F-75006 Paris, France

来源：

NATURE REVIEWS DRUG DISCOVERY | 2012年 / 11卷 / 03期

关键词：

T-CELL RESPONSES; METASTATIC COLORECTAL-CANCER; GASTROINTESTINAL STROMAL TUMOR; FAVORABLE PROGNOSTIC-FACTOR; ACUTE MYELOGENOUS LEUKEMIA; IMATINIB MESYLATE; DENDRITIC CELLS; GROWTH-FACTOR; MACROPHAGE INFILTRATION; PEPTIDE VACCINATION;

D O I：

10.1038/nrd3626

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

It has recently become clear that the tumour microenvironment, and in particular the immune system, has a crucial role in modulating tumour progression and response to therapy. Indicators of an ongoing immune response, such as the composition of the intratumoural immune infiltrate, as well as polymorphisms in genes encoding immune modulators, have been correlated with therapeutic outcome. Moreover, several anticancer agents - including classical chemotherapeutics and targeted compounds - stimulate tumour-specific immune responses either by inducing the immunogenic death of tumour cells or by engaging immune effector mechanisms. Here, we discuss the molecular and cellular circuitries whereby cytotoxic agents can activate the immune system against cancer, and their therapeutic implications.

引用

页码：215 / 233

页数：19

共 229 条

[1] Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant [J].

Adams, Sylvia ;

O'Neill, David W. ;

Nonaka, Daisuke ;

Hardin, Elizabeth ;

Chiriboga, Luis ;

Siu, Kimberly ;

Cruz, Crystal M. ;

Angiulli, Angelica ;

Angiulli, Francesca ;

Ritter, Erika ;

Holman, Rose Marie ;

Shapiro, Richard L. ;

Berman, Russell S. ;

Berner, Natalie ;

Shao, Yongzhao ;

Manches, Olivier ;

Pan, Linda ;

Venhaus, Ralph R. ;

Hoffman, Eric W. ;

Jungbluth, Achim ;

Gnjatic, Sacha ;

Old, Lloyd ;

Pavlick, Anna C. ;

Bhardwaj, Nina .

JOURNAL OF IMMUNOLOGY, 2008, 181 (01) :776-784

[2] A Decrease of Regulatory T Cells Correlates With Overall Survival After Sunitinib-based Antiangiogenic Therapy in Metastatic Renal Cancer Patients [J].

Adotevi, Olivier ;

Pere, Helene ;

Ravel, Patrice ;

Haicheur, Nacilla ;

Badoual, Cecile ;

Merillon, Nathalie ;

Medioni, Jacques ;

Peyrard, Severine ;

Roncelin, Stephane ;

Verkarre, Virginie ;

Mejean, Arnaud ;

Fridman, Wolf H. ;

Oudard, Stephane ;

Tartour, Eric .

JOURNAL OF IMMUNOTHERAPY, 2010, 33 (09) :991-998

[3] Correlation of the autoantibody response to the ALK oncoantigen in pediatric anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with tumor dissemination and relapse risk [J].

Ait-Tahar, Kamel ;

Damm-Welk, Christine ;

Burkhardt, Birgit ;

Zimmermann, Martin ;

Klapper, Wolfram ;

Reiter, Alfred ;

Pulford, Karen ;

Woessmann, Wilhelm .

BLOOD, 2010, 115 (16) :3314-3319

[4] AZGP1 Autoantibody Predicts Survival and Histone Deacetylase Inhibitors Increase Expression in Lung Adenocarcinoma [J].

Albertus, Daniel L. ;

Seder, Christopher W. ;

Chen, Guoan ;

Wang, Xiaoju ;

Hartojo, Wibisono ;

Lin, Lin ;

Silvers, Amy ;

Thomas, Daffyd G. ;

Giordano, Thomas J. ;

Chang, Andrew C. ;

Orringer, Mark B. ;

Bigbee, William L. ;

Chinnaiyan, Arul M. ;

Beer, David G. .

JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (11) :1236-1244

[5] Tumor-infiltrating cells as a prognostic factor in Hodgkin's lymphoma:: A quantitative tissue microarray study in a large retrospective cohort of 267 patients [J].

Alvaro-Naranjo, T ;

Lejeune, M ;

Salvadó-Usach, MT ;

Bosch-Príncep, R ;

Reverter-Branchat, G ;

Jaén-Martínez, J ;

Pons-Ferré, LE .

LEUKEMIA & LYMPHOMA, 2005, 46 (11) :1581-1591

[6] Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy [J].

Apetoh, Lionel ;

Ghiringhelli, Francois ;

Tesniere, Antoine ;

Obeid, Michel ;

Ortiz, Carla ;

Criollo, Alfredo ;

Mignot, Gregoire ;

Maiuri, M. Chiara ;

Ullrich, Evelyn ;

Saulnier, Patrick ;

Yang, Huan ;

Amigorena, Sebastian ;

Ryffel, Bernard ;

Barrat, Franck J. ;

Saftig, Paul ;

Levi, Francis ;

Lidereau, Rosette ;

Nogues, Catherine ;

Mira, Jean-Paul ;

Chompret, Agnes ;

Joulin, Virginie ;

Clavel-Chapelon, Francoise ;

Bourhis, Jean ;

Andre, Fabrice ;

Delaloge, Suzette ;

Tursz, Thomas ;

Kroemer, Guido ;

Zitvogel, Laurence .

NATURE MEDICINE, 2007, 13 (09) :1050-1059

[7] Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta [J].

Apperley, JF ;

Gardembas, M ;

Melo, JV ;

Russell-Jones, R ;

Bain, BJ ;

Baxter, J ;

Chase, A ;

Chessells, JM ;

Colombat, M ;

Dearden, CE ;

Dimitrijevic, S ;

Mahon, FX ;

Marin, D ;

Nikolova, Z ;

Olavarria, E ;

Silberman, S ;

Schultheis, B ;

Cross, NCP ;

Goldman, JM .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (07) :481-487

[8] A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer [J].

Arlen, PM ;

Gulley, JL ;

Parker, C ;

Skarupa, L ;

Pazdur, M ;

Panicali, D ;

Beetham, P ;

Tsang, KY ;

Grosenbach, DW ;

Feldman, J ;

Steinberg, SM ;

Jones, E ;

Chen, C ;

Marte, J ;

Schlom, J ;

Dahut, W .

CLINICAL CANCER RESEARCH, 2006, 12 (04) :1260-1269

[9] Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? [J].

Arnould, L ;

Gelly, M ;

Penault-Llorca, F ;

Benoit, L ;

Bonnetain, F ;

Migeon, C ;

Cabaret, V ;

Fermeaux, V ;

Bertheau, P ;

Garnier, J ;

Jeannin, JF ;

Coudert, B .

BRITISH JOURNAL OF CANCER, 2006, 94 (02) :259-267

[10] Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido [J].

Balachandran, Vinod P. ;

Cavnar, Michael J. ;

Zeng, Shan ;

Bamboat, Zubin M. ;

Ocuin, Lee M. ;

Obaid, Hebroon ;

Sorenson, Eric C. ;

Popow, Rachel ;

Ariyan, Charlotte ;

Rossi, Ferdinand ;

Besmer, Peter ;

Guo, Tianhua ;

Antonescu, Cristina R. ;

Taguchi, Takahiro ;

Yuan, Jianda ;

Wolchok, Jedd D. ;

Allison, James P. ;

DeMatteo, Ronald P. .

NATURE MEDICINE, 2011, 17 (09) :1094-U99

← 1 2 3 4 5 6 7 8 9 10 →